Project Grant R44CA298522
Award Date 9/4/25
Completion Date 8/31/27
Dollars Obligated $985K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,379,442 to Embiosys Inc. from September 2025 to August 2027 to develop and evaluate a novel wearable device that delivers induced electric field (IEF) therapy for the treatment of triple-negative breast cancer (TNBC). The key product being developed is a wearable, washable garment (camisole/tank-top) that can deliver low-intensity, intermediate frequency electromagnetic radiation...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $303,475 to Pulse Biosciences, Inc. to develop a new two-component treatment for pancreatic ductal adenocarcinoma (PDAC). The primary objectives are to: 1) Deliver nanosecond electric pulses to pancreatic tumors using endoscopic ultrasound-guided bipolar catheters to trigger immunogenic cell death, and 2) Inject an immune system stimulant into the tumor to generate an in situ...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This $399,300 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an innovative cancer immunotherapy approach at Tiba Biotech LLC, a biotechnology company based in Cambridge, Massachusetts. Specifically, the grant funds the creation of a targeted delivery system that combines enhanced self-amplifying RNA (esRNA) technology and spleen-targeting nanoparticle delivery materials. This platform is designed to stimulate a...
- The National Cancer Institute (NCI) awarded Gigamune, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentiviral vector for enhanced in vivo delivery of T cell receptors for cell therapy to treat Stage IV melanoma. The project aims to address challenges with current autologous T cell therapies, such as high costs and limited manufacturing capacity, by engineering innovative gene delivery methods to potentially increase patient access...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will fund the development and first clinical trial of an innovative Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel technology. The $998,781 award, with a project period from September 2025 to November 2026, aims to extend the use of local radiotherapy from palliative to potential distant...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research CFDA program (93.394), has awarded a $3,036,844 Project Grant to the University of Southern California (USC) to develop a wireless, wearable thermo-activator device for precise, localized control of chimeric antigen receptor (CAR) T cell therapy in solid tumors. The project aims to overcome limitations of current MRI-guided focused ultrasound approaches by creating a flexible, portable system that can remotely...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...